- Home
- EXEL vs PEN Comparison
EXEL vs PEN Comparison
Compare EXEL & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- PEN
- Stock Information
- Founded
- EXEL 1994
- PEN 2004
- Country
- EXEL United States
- PEN United States
- Employees
- EXEL N/A
- PEN N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- PEN Medical/Dental Instruments
- Sector
- EXEL Health Care
- PEN Health Care
- Exchange
- EXEL Nasdaq
- PEN Nasdaq
- Market Cap
- EXEL 9.4B
- PEN 10.0B
- IPO Year
- EXEL 2000
- PEN 2015
- Fundamental
- Price
- EXEL $36.85
- PEN $291.61
- Analyst Decision
- EXEL Buy
- PEN Buy
- Analyst Count
- EXEL 18
- PEN 16
- Target Price
- EXEL $37.24
- PEN $287.07
- AVG Volume (30 Days)
- EXEL 2.5M
- PEN 509.6K
- Earning Date
- EXEL 02-11-2025
- PEN 02-18-2025
- Dividend Yield
- EXEL N/A
- PEN N/A
- EPS Growth
- EXEL 170.77
- PEN N/A
- EPS
- EXEL 1.76
- PEN 0.36
- Revenue
- EXEL $2,168,701,000.00
- PEN $1,194,615,000.00
- Revenue This Year
- EXEL $5.36
- PEN $13.65
- Revenue Next Year
- EXEL $10.59
- PEN $14.30
- P/E Ratio
- EXEL $20.87
- PEN $811.72
- Revenue Growth
- EXEL 18.49
- PEN 12.86
- 52 Week Low
- EXEL $20.14
- PEN $148.00
- 52 Week High
- EXEL $37.59
- PEN $310.00
- Technical
- Relative Strength Index (RSI)
- EXEL 65.59
- PEN 65.03
- Support Level
- EXEL $34.01
- PEN $264.82
- Resistance Level
- EXEL $35.46
- PEN $310.00
- Average True Range (ATR)
- EXEL 1.09
- PEN 7.93
- MACD
- EXEL 0.36
- PEN 2.79
- Stochastic Oscillator
- EXEL 95.70
- PEN 64.07
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About PEN Penumbra Inc.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.